Leadership transition sets the stage for NUZ-001’s pivotal moment
Neurizon Therapeutics (ASX: NUZ) confirmed on 1 October 2026 that Dr Chris Bremer has formally commenced as Chief Executive Officer, with Sergio Duchini simultaneously transitioning from Interim Executive Chairman to Non-Executive Chairman. The leadership restructure arrives at a deliberate moment, with Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial now fully enrolled and topline results expected in late Q2 CY2027.
Regimen I has completed enrolment with 250 participants across 78 clinical sites in the United States. With the trial progressing towards its readout, the incoming CEO steps into a role shaped by the clinical, regulatory, and commercial preparation work that may follow the data.
When big ASX news breaks, our subscribers know first
Who is Dr Chris Bremer?
Dr Bremer brings more than 20 years of international pharmaceutical and biotechnology leadership experience spanning drug development, portfolio strategy, commercialisation, and business development. His career includes approximately 20 years at Grünenthal, where he held a series of senior global executive roles including Executive Vice President, Early Products & Commercial Opportunities and Interim Chief Commercial Officer.
Throughout his career, Dr Bremer has worked at the intersection of scientific development and commercial strategy. He has executed more than US$1 billion in licensing transactions, a track record that signals direct relevance to Neurizon’s potential partnering pathways ahead of the trial readout.
His experience across pharmaceutical development, commercial strategy, and business development is closely aligned with what Neurizon requires as the company prepares for the potential regulatory, partnering, and commercial pathways that may follow the clinical data.
Dr Chris Bremer, Chief Executive Officer
“I am delighted to formally commence as CEO of Neurizon at an important point in the Company’s development. Neurizon has established a strong foundation around NUZ-001, with an advanced clinical program and an international network spanning clinical development, regulatory, manufacturing and scientific capabilities.
“My immediate priority is disciplined execution as Regimen I progresses towards topline results. At the same time, we need to ensure that Neurizon is prepared to respond to the potential regulatory, development and strategic pathways that may emerge from the data…”
What is ALS and why does this trial matter?
ALS, or Amyotrophic Lateral Sclerosis, is the most common form of Motor Neurone Disease (MND). It is a progressive neurological condition that causes the nerve cells controlling movement to deteriorate over time, leading to loss of muscle function. There are currently very limited treatment options available, and the condition carries a serious prognosis.
A registrational Phase 2/3 trial is a clinical study designed with the statistical rigour and regulatory requirements necessary to potentially support an application for commercial approval, not purely exploratory research. It represents an advanced stage of clinical development.
The HEALEY ALS Platform Trial is a multi-arm, multi-site programme that evaluates multiple potential treatments simultaneously across major US clinical centres. This format allows several candidate therapies to be assessed within a shared infrastructure, improving efficiency and consistency of data collection. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.
NUZ-001 preclinical datasets presented at BIO 2026 in June showed consistent multi-pathway biological activity across human neurosphere and zebrafish models, with Phase 1 results from 12 patients demonstrating a 71% reduction in risk of death versus matched controls, the clinical foundation that underpins the HEALEY selection.
What comes next for Neurizon
Dr Bremer’s stated immediate priority is disciplined execution as Regimen I progresses towards topline results. In parallel, management is advancing workstreams across regulatory, manufacturing, partnering, and commercial readiness, subject to the clinical data.
Non-Executive Chairman Sergio Duchini framed the company’s current position in terms that investors will find material:
Sergio Duchini, Non-Executive Chairman
“On behalf of the Board, I am delighted to formally welcome Chris as Chief Executive Officer. Chris takes the leadership of Neurizon at an important stage, with enrolment in Regimen I complete, NIH-funded Expanded Access Program established, and the Company fully funded through the HEALEY readout and completion of the study. Our focus is now on maintaining disciplined execution while ensuring Neurizon is strategically prepared for the opportunities that may follow…”
Key upcoming milestones and events for investors to note:
- Topline results: Expected late Q2 CY2027
- Leadership Roundtable webinar: Thursday, 8 October 2026 at 4:00pm AEDT, featuring Dr Bremer and members of the Neurizon leadership team
- Register: https://bit.ly/neurizonroundtable
- Submit questions in advance: enquiries@neurizon.com
The webinar will include a live Q&A session, offering shareholders a direct opportunity to hear from the new CEO and the broader leadership team on the company’s priorities and the road ahead.
The broader leadership team has been reinforced over 2026 with the appointment of neurodegenerative disease expert Dr Ross Murdoch as Independent Non-Executive Director, adding more than 30 years of global pharmaceutical experience and deep US regulatory and commercial market knowledge to the Board ahead of the trial readout.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.